TOKYO & MUNICH & BASKING RIDGE, N.J. & NASHVILLE, Tenn.– Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today that the first patient has been dosed in the first-in-human phase 1 study evaluating DS-6000, a CDH6 directed antibody drug conjugate (ADC), in patients with advanced renal cell carcinoma or ovarian cancer with disease progression following standard treatment.
Despite recent advances in targeted treatment, five-year survival rates for both renal cell carcinoma and ovarian cancer remain low and new therapeutic strategies are needed for tumors that continue to progress on currently available medicines.1,2 CDH6 is a cadherin family protein overexpressed in several cancers, particularly renal cell and ovarian.3 CDH6 overexpression is associated with tumor growth and proliferation and has been correlated with poor prognosis in renal cell carcinoma.4 No CDH6 directed cancer therapies are currently approved.
“With DS-6000, we have applied our innovative DXd ADC technology to a promising molecular target, CDH6, and it has potential to serve as a new treatment modality for patients with renal cell or ovarian cancer,” said Arnaud Lesegretain, Vice President Oncology R&D and Head, Alpha Portfolio, Daiichi Sankyo. “We are pleased to continue our successful collaboration with Sarah Cannon, working together on advancing the development of another novel ADC with first-in-class potential.”
DS-6000 is the sixth DXd ADC from the oncology pipeline of Daiichi Sankyo to enter clinical development and the third being developed in collaboration with Sarah Cannon Research Institute.
“We look forward to developing DS-6000 as a potential treatment option for people facing renal cell carcinoma or ovarian cancer,” says Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology. “In partnership with Daiichi Sankyo, we will further evaluate whether DS-6000 may serve as a new and effective therapy for patients who have progressed on standard treatments.”
